Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ABL1 |
| Variant | amp |
| Impact List | none |
| Protein Effect | no effect |
| Gene Variant Descriptions | ABL1 amplification indicates an increased number of copies of the ABL1 gene. However, the mechanism causing the increase is unspecified. |
| Associated Drug Resistance | |
| Category Variants Paths |
ABL1 amp |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05751044 | Phase Ib/II | Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Venetoclax | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART B) | Recruiting | SWE | NOR | NLD | ITA | ISR | IRL | GBR | FRA | FIN | ESP | DNK | DEU | BEL | AUT | 0 |
| NCT02029001 | Phase II | Durvalumab + Tremelimumab Olaparib Nilotinib | Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (MOST plus) | Recruiting | FRA | 0 |